Study: CAD system useful in predicting length of recurrence-free cancer survival
A new study unveiled at RSNA this week has shown that the CADstream breast MRI system from Confirma is helpful in predicting the length of recurrence-free patient survival and supports the value of volumetric measurements of tumor response as a surrogate endpoint for survival outcomes, according to a release.

The study was undertaken at the University of California, San Francisco, led by Nola Hylton, PhD, which evaluated the automatic volume measurements that are part of CADstream. Hylton’s study was presented at RSNA this week. 

CADstream was developed in accordance with the American College of Radiology’s BI-RADS standards and has been utilized in a number of research projects and is currently in use by over 2000 physicians in more than 650 breast MRI programs, Confirma said.